Progressive supranuclear palsy - Clinical trials 

  • Clinical trials

Clinical trials for Progressive supranuclear palsy

Information provided by WHO International Clinical Trials Registry

The clinical trials below are relevant to Progressive supranuclear palsy. For all clinical trials, go to clinical trials search

This list shows clinical trials for Progressive supranuclear palsy

Search result filters
Recruitment status
Trials for children:
Country of trial:

You have searched for the following terms

  • Progressive supranuclear palsy
Title Recruitment status Location
Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP) Recruiting United Kingdom
A double-blind, placebo-controlled, randomized, parallel-group study evaluating the safety, tolerability and efficacy of two different oral doses of NP031112, a GSK-3 inhibitor, versus placebo in the treatment of patients with mild to moderate Progressive Supranuclear Palsy. - TAUROS Not Recruiting United Kingdom
Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy Not recruiting United Kingdom
A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal Degeneration Not recruiting United Kingdom
Open-label, multicentre study to assess the persistence on treatment in women with postmenopausal osteoporosis receiving once-monthly ibandronic acid with either a patient support programme (PSP) or bone turnover marker monitoring (BM) Not recruiting United Kingdom
Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS) Not recruiting United Kingdom
Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy Not recruiting United Kingdom
Estudio doble-ciego, controlado con placebo, aleatorizado, de grupos paralelos, para evaluar la seguridad, tolerancia y eficacia de dos dosis orales diferentes de NP031112, un inhibidor de GSK3, versus placebo, como tratamiento de pacientes con Parálisis Supranuclear Progresiva leve o moderada Authorised United Kingdom
A double-blind, placebo-controlled, randomized, parallel-group study evaluating the safety, tolerability and efficacy of two different oral doses of NP031112, a GSK-3 inhibitor, versus placebo in the treatment of patients with mild to moderate Progressive Supranuclear Palsy. - TAUROS Authorised United Kingdom
A Phase 2/3, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy. Authorised United Kingdom
  • Link to Directgov – public services all in one place
  • The Information Standard - Certified member